Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: A comparison to all-trans retinoic acid treatment

Internal Medicine

Volumn 44, Issue 8, 2005, Pages 818-824

  Shinjo, Kaori ^a   Takeshita, Akihiro ^a   Sahara, Naohi ^a   Kobayashi, Miki ^a   Nakamura, Satoki ^a   Shigeno, Kazuyuki ^a   Naito, Kensuke ^a   Maekawa, Masato ^a   Ohnishi, Kazunori ^a   Ohno, Ryuzo ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Laboratory data

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; GABEXATE MESILATE; HEMOGLOBIN; RETINOIC ACID;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG RESPONSE; ECG ABNORMALITY; ERYTHROCYTE COUNT; FEMALE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEART VENTRICLE TACHYCARDIA; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; LIVER DYSFUNCTION; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PERIPHERAL NEUROPATHY; PROMYELOCYTIC LEUKEMIA; PRURITUS; QT PROLONGATION; RETINOIC ACID SYNDROME; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; VOMITING;

ANTINEOPLASTIC AGENTS; ARSENICALS; BLOOD COAGULATION; ERYTHROCYTE COUNT; HEMATOPOIESIS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; LEUKOCYTES; OXIDES; PLATELET COUNT; TIME FACTORS; TRETINOIN;

EID: 24644500777     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.818     Document Type: Article

References (24)

1. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
2. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76: 1704-1709, 1990.
3. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385-1393, 1991.
4. Ohno R, Ohnishi K, Takeshita A, et al. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 8 (suppl. 3): s64-s69, 1994.
5. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85: 1202-1206, 1995.
6. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Group. J Clin Oncol 16: 78-85, 1998.
7. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17: 1454-1463, 2003.
8. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
9. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324, 1999.
10. 3: an experience of 120 patients at a single institution. Int J Hematol 70: 248-260, 1999.
11. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860, 2001.
12. Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 16: 617-622, 2002.
13. Liu P, Han ZC. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol 78: 32-39, 2003.
14. Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid-or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission. Oncogene 20: 7257-7265, 2001.
15. Miller WH Jr, Waxman S. Differentiation induction as a treatment for hematologic malignancies. Oncogene 21: 3496-3506, 2002.
16. 3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353, 1997.
17. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
18. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14: 262-270, 2000.
19. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 38: 26-36, 2001.
20. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903, 2002.
21. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 88: 1052-1061, 1996.
22. Shen Y, Shen ZX, Yan H, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15: 735-741, 2001.
23. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101: 5328-5335, 2004.
24. Zhao W, Wang H, Wang X, et al. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thromb Res 102: 197-204, 2001.